^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | ZEN-3694 (BET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 1282: Overcoming resistance to inhibitors of CDK4/6 and BET in estrogen receptor-positive breast cancer
Published date:
05/15/2020
Excerpt:
14 breast cancer PDXs (10 ER+/HER2- and 4 ER+/HER2+) that were resistant to CDK4/6i in vivo were treated with ZEN-3694, a selective BET inhibitor currently in clinical development. Nine of the PDXs were sensitive to BET inhibition in monotherapy (65%).
DOI:
10.1158/1538-7445.AM2020-1282
